Neurorehabilitation News

The American Brain Foundation has announced the launch of a $10 million cross-disciplinary research initiative for neuroscientists to investigate the role of neuroinflammation in a wide range of neurologic and psychiatric brain diseases.

The FDA has cleared an investigational new drug application for AVB-101 to treat those with frontotemporal dementia with mutations in the progranulin gene, according to a release from the manufacturer.

Nido Biosciences has announced positive results from a phase 1 study of its novel, small molecule therapeutic to treat spinal and bulbar muscular atrophy in healthy male participants.

A Bay Area neurotechnology firm has announced the commercial release of a novel artificial intelligence-based software algorithm that continuously monitors brain activity of those with electrographic status epilepticus.

DENVER — Addiction expert Anna Lembke, MD, invited the Lifestyle Medicine 2023 health care audience to do a 24-hour fast from their smartphones and other digital devices.

The FDA has approved a 40 mg/mL oral suspension of Agamree to treat Duchenne muscular dystrophy in patients aged 2 years and older, according to a release from the manufacturer.

Beckley Psytech announced dosing of the first patient in a phase 2b clinical trial of BPL-003, an intranasal synthetic formulation of the psychedelic compound 5-MeO-DMT for treatment-resistant depression.

Ecopipam, a novel investigational compound for central nervous system disorders significantly reduced symptoms of Tourette syndrome in a cohort of pediatric patients, according to the manufacturer.

For individuals exposed to athletic-related head contact, glial fibrillary acidic protein may help identify those who are at risk for progressive regional brain atrophy and cognitive decline, per data from Alzheimer’s Research & Therapy.

The FDA has approved UCB’s Zilbrysq for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.